BOSTON, March 31, 2015 /PRNewswire/
-- PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today introduced the
latest version of its Regulatory Information Management (RIM)
platform: LIQUENT InSight® 6.0. The LIQUENT InSight
platform supports the entire regulatory product lifecycle,
from early planning of registration targets through product
retirement, with robust submission planning, publishing, viewing
and registration management capabilities.
While biopharmaceutical companies and the patients who can
benefit from new drugs are located throughout the world, there is
no single international regulatory body to review and approve new
medicine applications. For new and innovative medicines to
successfully reach patients and maintain regulatory compliance
throughout the product lifecycle, biopharmaceutical companies must
navigate the complex, global regulatory and region-specific
regulations.
"LIQUENT InSight 6.0 simplifies navigation of the global
regulatory environment and provides the submission and registration
management tools needed to more quickly bring treatments to market
and effectively maintain them throughout their lifespan," said
Xavier Flinois, President, PAREXEL Informatics. "As an essential
part of the drug development journey, the LIQUENT InSight platform
centralizes a company's regulatory information to drive
standardization, improve collaboration, and helps to ensure
compliance, eliminate waste, reduce costs, and increase
efficiencies so more patients can quickly and safely receive the
treatments they need."
Enhancements to the LIQUENT InSight platform include:
- Business Intelligence: added robust analytics to enhance
reporting capabilities
- Usability: simplified interface designed by usability experts
provide an intuitive experience to all levels of InSight users
- Compliance: updated data model and architecture helps to ensure
processes, output and work product compliance with standards such
as XEVMPD and the upcoming IDMP mandate
- Interoperability: revamped interoperability web services
features that help systems interact and communicate with each
other
Since the market introduction of LIQUENT InSight in 2004, more
than 40 companies (including 14 of the top 20 pharmaceutical
companies) have selected the LIQUENT InSight platform as their
single source of regulatory information. PAREXEL's RIM technologies
can also be coupled with comprehensive professional services from
PAREXEL® Consulting, which provides a full complement of
Regulatory Outsourcing Services to help companies meet the demands
of today's complex and changing regulatory environment.
LIQUENT InSight 6.0 will also be available through the
Perceptive® Partner Program.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston, Massachusetts, PAREXEL operates in 81
locations in 51 countries around the world, and has approximately
16,530 employees. For more information about PAREXEL
International visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, Perceptive, and LIQUENT InSight
are trademarks or registered trademarks of PAREXEL International
Corporation or its affiliates.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisition of ClinIntel Limited, or enter into new
lines of business; the impact on the Company's business of
government regulation of the drug, medical device and
biotechnology industry; consolidation within the pharmaceutical
industry and competition within the biopharmaceutical services
industry; the potential for significant liability to clients and
third parties; the potential adverse impact of health care reform;
and the effects of foreign currency exchange rate fluctuations and
other international economic, political, and other
risks. Such factors and others are discussed more fully
in the section entitled "Risk Factors" of the Company's Quarterly
Report on Form 10-Q for the quarter ended December 31,
2015 as filed with the Securities and Exchange Commission
on February 5, 2015, which "Risk Factors" discussion is
incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
PAREXEL
International
Tel: +1
781-434-5516
Email: Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
Matthew Briggs, PAN
Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-launches-liquent-insight-60-regulatory-information-management-platform-300057858.html
SOURCE PAREXEL International Corporation